Lipocine Fundamentals

LPCN -  USA Stock  

USD 1.17  0.04  3.54%

Lipocine fundamentals help investors to digest information that contributes to Lipocine's financial success or failures. It also enables traders to predict the movement of Lipocine Stock. This fundamental analysis module provides a way for investors to measures Lipocine's intrinsic value by examining all of its available economic and financial indicators and drivers, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lipocine stock. Please note, this module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Lipocine Fundamentals 

 
Refresh
Lipocine Income Tax Expense is quite stable at the moment as compared to the past year. The company's current value of Income Tax Expense is estimated at 248.16.

Lipocine Price to Earning Analysis

Lipocine's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
 2018 2019 2020 2021 (projected)
Enterprise Value28.3 M6.05 M77.75 M69.36 M
Average Equity12.94 M9.05 M12.37 M15.1 M
P/E 
 = 
Market Value Per Share 
Earnings Per Share 
More About Price to Earning | All Equity Analysis

Current Lipocine Price to Earning

    
  (11.04) X  
Most of Lipocine's fundamental indicators, such as Price to Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lipocine is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Compare to competition

Lipocine Accumulated Retained Earnings Deficit

Accumulated Retained Earnings Deficit

(176.56 Million)Share
Lipocine Accumulated Retained Earnings Deficit are quite stable at the moment as compared to the past year. The company's current value of Accumulated Retained Earnings Deficit is estimated at (176.56 Million)
Based on the latest financial disclosure, the price to earning indicator of Lipocine is roughly -11.0389 times. This is 142.72% lower than that of the Healthcare sector and notably lower than that of the Biotechnology industry. The price to earning for all United States stocks is 138.44% higher than that of the company.

Lipocine Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Lipocine's current stock value. Our valuation model uses many indicators to compare Lipocine value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lipocine competition to find correlations between indicators driving Lipocine's intrinsic value. More Info.
Lipocine is rated third overall in working capital category among related companies. It is rated second overall in current valuation category among related companies reporting about  2.44  of Current Valuation per Working Capital. Lipocine Working Capital is quite stable at the moment as compared to the past year. The company's current value of Working Capital is estimated at 22.16 Million. Comparative valuation analysis is a catch-all model that can be used if you cannot value Lipocine by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Lipocine's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lipocine's earnings, one of the primary drivers of an investment's value.

Lipocine Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lipocine's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lipocine could also be used in its relative valuation, which is a method of valuing Lipocine by comparing valuation metrics of similar companies.
Lipocine is currently under evaluation in return on equity category among related companies.

Lipocine Current Valuation Drivers

We derive many important indicators used in calculating different scores of Lipocine from analyzing Lipocine's financial statements. These drivers represent accounts that assess Lipocine's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Lipocine's important valuation drivers and their relationship over time.
201620172018201920202021 (projected)
Net Income Per Employee(1.35 M)(1.5 M)(1.17 M)(1.08 M)(1.25 M)(1.34 M)
Average Assets32.25 M26.71 M25.13 M19.92 M23.65 M27.14 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(18.94 M)(20.95 M)(11.64 M)(12.22 M)(20.57 M)(22.2 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(18.94 M)(20.95 M)(11.64 M)(12.22 M)(20.57 M)(22.2 M)
Earnings before Tax(18.97 M)(20.98 M)(11.66 M)(13.01 M)(20.96 M)(21.52 M)
Average Equity30.14 M23.19 M12.94 M9.05 M12.37 M15.1 M
Enterprise Value62.49 M63.65 M28.3 M6.05 M77.75 M69.36 M
Free Cash Flow(18.34 M)(16.7 M)(12.08 M)(11.67 M)(15.3 M)(16.51 M)
Invested Capital20.46 M15.77 M13.54 M7.11 M142.07 K145.81 K
Invested Capital Average20.95 M14.18 M21.61 M11.44 M4.36 M4.47 M
Market Capitalization67.2 M72.92 M27.9 M9.78 M89.33 M81.84 M
Tangible Asset Value27.34 M25.33 M20.85 M19.66 M25.35 M27.45 M
Working Capital25.88 M18.87 M16.32 M14.67 M18.75 M22.16 M

Lipocine Fundamentals

About Lipocine Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Lipocine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lipocine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lipocine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2021
Revenues148.5 K152.4 K
Revenue to Assets 0.009652  0.0135 
Revenue Per Employee15.8 K24.7 K
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. The companys pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase II Clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis TLANDO XR, an oral prodrug of testosterone for once daily dosing, which has completed Phase II clinical trial in hypogonadal men LPCN 1148, an oral prodrug of bioidentical testosterone that has completed phase I clinical trial for the treatment of NASH cirrhosis and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. Lipocine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.

Lipocine Investors Sentiment

The influence of Lipocine's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Lipocine. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Lipocine Implied Volatility

    
  240.72  
Lipocine's implied volatility exposes the market's sentiment of Lipocine stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Lipocine's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Lipocine stock will not fluctuate a lot when Lipocine's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lipocine in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lipocine's short interest history, or implied volatility extrapolated from Lipocine options trading.

Current Sentiment - LPCN

Lipocine Investor Sentiment

Most of Macroaxis users are now bullish on Lipocine. What is your trading attitude regarding investing in Lipocine? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Lipocine using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Lipocine Piotroski F Score and Lipocine Altman Z Score analysis. Note that the Lipocine information on this page should be used as a complementary analysis to other Lipocine's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Complementary Tools for Lipocine Stock analysis

When running Lipocine price analysis, check to measure Lipocine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipocine is operating at the current time. Most of Lipocine's value examination focuses on studying past and present price action to predict the probability of Lipocine's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Lipocine's price. Additionally, you may evaluate how the addition of Lipocine to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Is Lipocine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine Lipocine value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.